A closer look at liver health.
Your liver health can change over time, and symptoms may not be noticeable. This test is designed to look for patterns that may be associated with metabolic-related liver risk for people who may be at higher risk for metabolic related fatty liver conditions, such as Metabolic Dysfunction-Associated Steatohepatitis (MASH), which is often linked to factors like type 2 diabetes or abnormal metabolic health markers.
The NASHnext® Advanced Liver Risk Test measures a combination of blood based biomarkers associated with fat buildup in the liver, inflammation, and liver scarring (fibrosis). These markers are analyzed together using an advanced algorithm to estimate the likelihood of metabolic related liver conditions such as MASH, previously called nonalcoholic steatohepatitis (NASH) and moderate to advanced fibrosis.
Unlike standard liver enzyme tests like ALT (Alanine Aminotransferase) and AST (Aspartate Aminotransferase)—which measure a limited set of markers and may be within normal range even when liver changes are present—this advanced blood test looks at multiple markers.
Note: Results are not diagnostic and cannot tell whether you have liver disease. Instead, they are intended to help support follow-up discussions with a healthcare provider.
This test is not intended for people whose liver concerns are likely caused by other conditions, including viral hepatitis, alcohol related liver disease, medication related liver injury, genetic or autoimmune liver diseases, or certain bile duct disorders.
Preparation: Fast for 12 hours (no food or drink, except water) before sample collection.
This test evaluates multiple blood-based markers associated with liver fat, inflammation, and liver fibrosis. Unlike routine liver enzyme tests alone, this approach looks at how several markers relate to each other. Results are intended to support clinical follow-up and monitoring decisions when interpreted by a healthcare provider and are only one part of a broader liver health evaluation.
This advanced liver risk test provides insight into your likelihood of liver fibrosis and inflammation by evaluating patterns in your blood linked to metabolic liver disease. Results are reported as risk categories, helping you better understand where you may fall on the liver health spectrum.
Many people with fatty liver disease feel well and may not notice symptoms, especially early on. This test may help estimate liver-related risk and is most appropriate for people with known risk factors.
If you’re managing conditions like type 2 diabetes, metabolic syndrome, or elevated cholesterol, this MASH blood test can offer useful insights to guide discussions with your healthcare provider.
1. American College of Gastroenterology. Steatotic liver disease (MASLD). Updated April 24, 2026. https://gi.org/topics/steatotic-liver-disease-masld/
2. Harrison SA, Anstee QM, Bedossa P, et al. A blood-based biomarker panel (NIS4) for noninvasive diagnosis of nonalcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(11):970-985. doi:10.1016/S2468-1253(20)30252-1
3. Sanyal AJ, Shringarpure R, Reddy KG, et al. Diagnostic performance of circulating biomarkers for nonalcoholic steatohepatitis. Nat Med. 2023;29(10):2656-2664. doi:10.1038/s41591-023-02539-6
4. National Institute of Diabetes and Digestive and Kidney Diseases. Nonalcoholic Fatty Liver Disease (NAFLD) & NASH. Updated April 2021. Accessed May 5, 2026. https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash
5. Labcorp. NASHnextTM (test no. 504960). Accessed May 5, 2026. https://www.labcorp.com/tests/504960/nashnext
<p>1. American College of Gastroenterology. Steatotic liver disease (MASLD). Updated April 24, 2026. <a rel="noopener noreferrer" title="liver-disease-masld" target="_blank" href="https://gi.org/topics/steatotic-liver-disease-masld">https://gi.org/topics/steatotic-liver-disease-masld/</a></p> <p>2. Harrison SA, Anstee QM, Bedossa P, et al. A blood-based biomarker panel (NIS4) for noninvasive diagnosis of nonalcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>Lancet Gastroenterol Hepatol.</i> 2020;5(11):970-985. doi:10.1016/S2468-1253(20)30252-1</p> <p>3. Sanyal AJ, Shringarpure R, Reddy KG, et al. Diagnostic performance of circulating biomarkers for nonalcoholic steatohepatitis. <i>Nat Med</i>. 2023;29(10):2656-2664. doi:10.1038/s41591-023-02539-6</p> <p>4. National Institute of Diabetes and Digestive and Kidney Diseases. Nonalcoholic Fatty Liver Disease (NAFLD) & NASH. Updated April 2021. Accessed May 5, 2026. <a rel="noopener noreferrer" title="nafld-nash" target="_blank" href="https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash">https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash</a></p> <p>5. Labcorp. NASHnext<sup>TM</sup> (test no. 504960). Accessed May 5, 2026. <a rel="noopener noreferrer" title="NASHnext test details" href="https://www.labcorp.com/tests/504960/nashnext" target="_blank">https://www.labcorp.com/tests/504960/nashnext</a></p>
Simply purchase this test online. A healthcare provider will review and approve your test requests; no healthcare provider visit is required.
Visit a Labcorp location near you for sample collection. Visits may be scheduled online.
View your easy-to-read results online in your Labcorp Patient™ account, including Linked Accounts. For certain results that require prompt attention, you will also be contacted by phone or mail.
Learn more about your risk for liver disease with this accurate, reliable liver health test.
Evaluate your liver health with a GGT blood test.
Assess your kidney health with a blood test for eGFR, creatinine, albumin and ACR.
Test key men's biomarkers for in-depth hormonal, metabolic and heart health insights.
Explore key biomarkers to gain insights into hormonal, metabolic and heart health for women.
The Labcorp OnDemand Liver Health Test focuses on liver function by measuring enzymes and proteins like ALT, AST, bilirubin, and albumin and includes a FIB‑4 score to screen for fibrosis risk. NASHnext® is more specialized; it uses advanced biomarkers and a proprietary algorithm to estimate risk specifically related to MASH and moderate to advanced fibrosis. Both tests offer valuable insight. NASHnext® is designed for a deeper look at metabolic‑related liver risk.
A NASH profile blood test looks at multiple blood‑biomarkers together to estimate risk for metabolic dysfunction‑associated steatohepatitis and liver fibrosis. The NASHnext® test uses a validated algorithm (NIS4) that combines markers associated with liver inflammation, metabolic health, and scarring into a single risk score. This approach provides a more nuanced picture of liver health and risk for advanced liver complications compared to routine liver enzyme tests.
While this test can provide useful information, it is not diagnostic and cannot confirm or rule out NASH/MASH. Imaging tests or other evaluations may still be recommended by a healthcare provider depending on your risk level and medical history.
This test is designed for people who may be at higher risk for metabolic‑related fatty liver conditions, such as MASH, which is often linked to factors like type 2 diabetes or abnormal metabolic health markers.
It is not intended for people whose liver concerns are likely caused by other conditions, including viral hepatitis, alcohol‑related liver disease, medication‑related liver injury, genetic or autoimmune liver diseases, or certain bile duct disorders.
If you’re unsure whether this test is right for you, a healthcare provider can help determine whether this test is appropriate for you based on your health history and other test results.
The NASHnext™ score combines information from four blood markers into a single number that helps estimate liver‑related risk. Each marker gives a different piece of information about liver health:
Together, these markers are analyzed to place results into risk categories, offering context about your liver health. The score does not diagnose liver disease and should be discussed with a healthcare provider as part of a full health evaluation.
Many people never develop noticeable symptoms, which is why fatty liver disease is often found during testing done for other reasons.
When symptoms do occur, they may include1:
There isn’t a single blood test that definitively confirms NASH/MASH. Tests like the NASHnext® Advanced Liver Risk Test combine multiple specialized biomarkers into a risk score, offering more advanced insights about your liver health.
This test does not provide a diagnosis but can help identify people who may be at lower or higher risk and support next step conversations with a healthcare provider.
Not necessarily. Elevated ALT and AST can be linked to fatty liver, but they can also rise due to other factors or remain normal despite underlying liver changes. That’s why more advanced tests look beyond enzymes to provide additional insight into fatty liver and fibrosis risk.
Yes. Many people with early or even moderate fibrosis have normal routine liver test results. Advanced blood‑based assessments can sometimes detect fibrosis related patterns before enzyme levels change, helping identify risk earlier.
Simple fatty liver involves fat buildup without significant inflammation. NASH/MASH includes inflammation and liver cell injury, which increases the risk of fibrosis over time. Identifying risk earlier can help guide monitoring and lifestyle discussions.
Your testing will be performed in a CLIA-certified clinical laboratory. Labcorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. Our labs perform regular quality assurance testing to ensure our results are accurate.
Your results will be provided to you through our secure online portal to view or print. Results are also made available through a secure portal to the independent healthcare provider who placed your test order. If you are accessing your results through your Labcorp Patient™ account, all users linked to the account will have access to all OnDemand test results. Results may also be provided to a local, state, and/or federal health authority; for example, many states require the testing laboratory and physician to report test results for certain communicable diseases, such as COVID-19, to local or state health departments.
If you have questions or comments regarding the Labcorp Notice of Privacy Practices, or have a complaint about our use or disclosure of your PHI or our privacy practices, please contact: privacyofficer@labcorp.com, call us at (877) 234-4722 (877-23-HIPAA) and ask for the Labcorp HIPAA Privacy Officer, or send a written request to: HIPAA Privacy Officer, Labcorp, 531 South Spring Street, Burlington, NC 27215. You also may file a complaint with the Secretary of the U.S. Department of Health and Human Services.
Visit the Labcorp OnDemand® website to browse and purchase laboratory tests and create your Labcorp Patient™ account to view your results. All Labcorp OnDemand testing requires an order from an authorized healthcare professional. For your convenience, Labcorp OnDemand has contracted with independent professional entities (collectively, Providers) to deliver healthcare provider services. Visit a Labcorp location for sample collection; or, if using an at-home collection kit, collect your sample yourself. We’ll let you know when your results are ready and can be accessed through your Labcorp Patient™ account.
To align with clinical best practices, we’ve set an age maximum of 100 for consumer-initiated testing. This limit was set to encourage individuals in more advanced age groups - who may have complex medical needs - to receive personalized guidance about testing from their healthcare providers.
